Opportunities Preloader

Please Wait.....

Report

Hepatitis B Vaccine Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

Market Report I 2025-07-04 I 140 Pages I Global Market Insights

The Global Hepatitis B Vaccine Market was valued at USD 6.7 billion in 2024 and is estimated to grow at a CAGR of 5.7% to reach USD 12 billion by 2034. The growth trajectory is largely influenced by the increasing number of hepatitis B cases worldwide, backed by government-backed vaccination campaigns and accelerated vaccine development efforts. National immunization programs and expanded public health awareness have led to greater access and uptake of vaccines across various age groups. Additionally, demand for more efficient and targeted solutions is pushing continuous innovation in vaccine formulation and manufacturing. Advances in recombinant technology and delivery mechanisms are contributing to higher efficacy, longer-lasting immunity, and reduced dosage requirements. As healthcare systems aim to reduce the burden of liver-related diseases, the market is witnessing stronger momentum for preventive vaccination, particularly among at-risk populations.
The rising preference for next-generation formulations that deliver robust and rapid immune responses further supports adoption globally. These advanced vaccines are being engineered with enhanced antigen stability, improved adjuvant systems, and optimized delivery methods to generate quicker and more sustained protection against hepatitis B. Unlike traditional formulations, next-gen vaccines aim to reduce the number of doses required for full immunity, making them more suitable for large-scale immunization campaigns, especially in regions with limited healthcare access. This innovation is particularly crucial for immunocompromised individuals and high-risk groups who may not respond effectively to conventional vaccines.
In 2024, the combination vaccines segment led the market with a value of USD 4.5 billion and is forecasted to reach USD 7.8 billion by 2034, growing at a CAGR of 5.5%. These multivalent vaccines combine hepatitis B protection with immunization against other infectious agents, reducing the number of injections required. This integrated approach improves patient compliance and simplifies vaccine schedules, especially for infants and children. As a result, combination vaccines have gained widespread adoption in pediatric healthcare, supported by both public and private immunization programs. Governments and providers increasingly opt for these vaccines due to their efficiency in administration, broader coverage, and cost advantages, helping raise vaccination rates across communities.
The male segment is expected to reach USD 7.1 billion by 2034. This is largely driven by biological and hormonal differences that increase the risk of chronic infection and liver-related complications in men. Testosterone has been shown to influence immune response and virus persistence, placing males at a greater risk of prolonged hepatitis B infection. As a result, immunization programs have increasingly focused on adult men, with widespread availability of adult vaccine formulations supporting this trend. Growing awareness, better access to healthcare, and a push for preventive care continue to accelerate vaccine adoption in this segment.
North America Hepatitis B Vaccine Market was valued at USD 2.7 billion in 2024 and is projected to reach USD 4.7 billion by 2034 at a CAGR of 5.4% through 2034. The region remains a dominant force in the global hepatitis B vaccine landscape due to its advanced healthcare delivery systems and high public awareness. Strong infrastructure, along with extensive government-backed vaccination programs, has enabled both pediatric and adult immunization rates to remain consistently high. The burden of hepatitis B remains significant, especially in vulnerable populations, prompting sustained efforts toward widespread prevention and early immunization coverage in countries like the U.S. and Canada.
Key market players include Serum Institute of India, VBI Vaccines, Sanofi, Biological E, YS Biopharma, GSK, Shenzhen Kangtai Biological Products, Bharat Biotech, Dynavax Technologies, Merck, and Gilead Sciences. To strengthen their market position, companies in the hepatitis B vaccine segment are focusing on product innovation, expanding their global distribution networks, and engaging in strategic partnerships.
Leading players are investing heavily in R&D to develop next-generation vaccines with improved safety profiles and stronger immunogenicity. Many are leveraging combination vaccine platforms to increase coverage and appeal to broader healthcare systems. Collaborations with government health agencies, NGOs, and international organizations are also enabling smoother vaccine rollouts in emerging markets.

Report Content

Chapter 1 Methodology and Scope
1.1 Market scope and definition
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Data mining sources
1.3.1 Global
1.3.2 Regional/Country
1.4 Base estimates and calculations
1.4.1 Base year calculation
1.4.2 Key trends for market estimation
1.5 Primary research and validation
1.5.1 Primary sources
1.6 Forecast model
1.7 Research assumptions and limitations

Chapter 2 Executive Summary
2.1 Industry 360 synopsis
2.2 Key market trends
2.2.1 Regional
2.2.2 Vaccine type
2.2.3 Age group
2.2.4 Gender
2.2.5 End use
2.3 CXO perspectives: Strategic imperatives
2.3.1 Key decision points for industry executives
2.3.2 Critical success factors for market players
2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.1.1 Supplier landscape
3.1.2 Value addition at each stage
3.1.3 Factors affecting the value chain
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising prevalence of liver diseases
3.2.1.2 Growing immunization coverage programs
3.2.1.3 Advancements in vaccine formulation and production efficiency
3.2.1.4 Increasing R&D investment and activities
3.2.2 Industry pitfalls and challenges
3.2.2.1 Stringent regulatory approval processes
3.2.2.2 High cost of storage and transportation of vaccine
3.2.3 Market opportunities
3.2.3.1 Growing public-private partnerships for vaccine distribution
3.2.3.2 Expanding adult vaccination programs
3.3 Growth potential analysis
3.4 Pipeline analysis
3.5 Regulatory landscape
3.6 Technological advancements
3.7 Future market trends
3.8 Porter's analysis
3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024
4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Key developments
4.6.1 Mergers and acquisitions
4.6.2 Partnerships and collaborations
4.6.3 Expansion plans

Chapter 5 Market Estimates and Forecast, By Vaccine Type, 2021 - 2034 ($ Mn)
5.1 Key trends
5.2 Single antigen vaccine
5.3 Combination vaccine

Chapter 6 Market Estimates and Forecast, By Age Group, 2021 - 2034 ($ Mn)
6.1 Key trends
6.2 Pediatric
6.3 Adult

Chapter 7 Market Estimates and Forecast, By Gender, 2021 - 2034 ($ Mn)
7.1 Key trends
7.2 Female
7.3 Male

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)
8.1 Key trends
8.2 Hospitals
8.2.1 Public
8.2.2 Private
8.3 Specialty clinics
8.4 Other end use

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE

Chapter 10 Company Profiles
10.1 Bharat Biotech
10.2 Biological E
10.3 Dynavax Technologies
10.4 Gilead Sciences
10.5 GSK
10.6 Merck
10.7 Sanofi
10.8 Serum Institute of India
10.9 Shenzhen Kangtai Biological Products
10.10 VBI vaccines
10.11 YS Biopharma

  • Not Sure / Need Reassuring
    • Confirm Content
      • Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:

        Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.

        Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.

        Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.

    • Sample Pages
      • With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.

        It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.

        To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Check for Alternatives
      • Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.

        To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.

  • Prices / Formats / Delivery
    • Prices
      • All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.

        Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Discounts
      • As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.

        Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.

        To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Available Currencies
      • Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.

        Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.

        To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.

    • Licenses
      • License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Global Site License
      • The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.

        It is important to note that this may exclude Parent Companies or Subsidiaries.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Formats
      • The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.

        If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.

    • Delivery
      • Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.

        Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.

        If a delay in delivery is expected you will be informed about it immediately.

    • Shipping Charges
      • As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.

        If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.

  • Ordering
    • By Credit Card
      • We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.

        Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.

        For more information on PayU please visit: https://www.payu.pl/en/about-us

    • By Money Transfer
      • If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.

        With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.

  • Security
    • Website security
      • We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.

        Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.

    • Credit Card Security
      • We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.

        PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.

PLEASE SELECT LICENSE